Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 2536 in advanced NSCLC
NCT00376623Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BI-2536 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Objective Tumour Response Evaluated According to RECIST 1.0 by Central Review up to 533 days. Started Jul 2006; status: completed.
02
Drugs
BI-2536
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00376623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376623.